Arthritis news. Anytime. Anywhere.

Call for patient input on IV form of certolizumab pegol for ankylosing spondylitis

Call for patient input on IV form of certolizumab pegol (Cimzia®) for ankylosing spondylitis

Do you have ankylosing spondylitis or care for someone who does? We need your valuable input.

Stick man holding megaphoneThe Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input on the manufacturer’s submission for the intravenous (IV) form of certolizumab pegol (Cimzia®) for the treatment of ankylosing spondylitis (AS). Certolizumab pegol has a Health Canada indication for use in combination with methotrexate for reducing signs and symptoms, inducing major clinical response, and reducing the progression of joint damage as assessed by x-ray, in adult patients with moderately to severely active rheumatoid arthritis (RA). It may be used alone for reducing signs and symptoms in patients with moderately to severely active RA who do not tolerate methotrexate.

The CDR is part of the Canadian Agency for Drugs and Technologies in Health (CADTH). The CDR conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides drug formulary recommendations to the publicly funded drug plans in Canada (except Quebec). 

To help them make their recommendations, the CDR accepts input from patient groups, like Arthritis Consumer Experts (ACE). Because patient input is vitally important to government decision-making about medications, we would like to gather your views and share them with the CDR. 

These are the questions they are asking:

Continue reading

Call for patient input on subcutaneous tocilizumab for rheumatoid arthritis

Call for patient input on subcutaneous tocilizumab (Actemra®) for rheumatoid arthritis

Do you have rheumatoid arthritis or care for someone who does? We need your valuable input.

Megaphone GraphicThe Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input on the manufacturer’s submission for subcutaneous (an injection under the skin) tocilizumab (Actemra®) for the treatment of rheumatoid arthritis (RA). The intravenous form (or “IV”) of tocilizumab is approved by Health Canada for the treatment of adults with moderately-to-severely active rheumatoid arthritis who have failed to respond to an adequate trial of both DMARDs and a tumor necrosis factor (TNF)-alpha inhibitor. 

The CDR is part of the Canadian Agency for Drugs and Technologies in Health (CADTH). The CDR conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides drug formulary recommendations to the publicly funded drug plans in Canada (except Quebec). 

To help them make their recommendations, the CDR accepts input from patient groups, like Arthritis Consumer Experts (ACE). Because patient input is vitally important to government decision-making about medications, we would like to gather your views and share them with the CDR. 

These are the questions they are asking:

Continue reading

Call for patient input on tofacitinib (Xeljanz®) for the treatment of rheumatoid arthritis

Do you have rheumatoid arthritis or care for someone who does? We need your valuable input.

Megaphone GraphicThe Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input on the manufacturer’s submission for tofacitinib (Xeljanz®) for the treatment of rheumatoid arthritis (RA). Tofacitinib is an oral disease-modifying anti-rheumatic drug (DMARD) that was issued a Notice of Compliance (NOC) from Health Canada on April 17, 2014. Tofacitinib in combination with methotrexate (MTX), is indicated for reducing the signs and symptoms of RA, in adult patients with moderately to severely active RA who have had an inadequate response to MTX. In cases of intolerance to MTX, physicians may consider the use of tofacitinib as monotherapy.

The CDR is part of the Canadian Agency for Drugs and Technologies in Health (CADTH). The CDR conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Quebec). 

To help them make their recommendations, the CDR accepts input from patient groups, like Arthritis Consumer Experts (ACE). We would like to gather your views and share them with the CDR.

These are the questions they are asking:

Continue reading

#Goals4Arthritis – Goal 31: You are the champion!

#Goals4Arthritis – Goal 31: You are the champion!

Regardless of who wins the FIFA World Cup championship game today in Estadio do Maracana Rio de Janeiro, Arthritis Broadcast Network expresses a big thank you to all of you who participated and shared your goals for arthritis. Today, we hope you enjoy the finals and crowning of a new World Cup champion.

As an organization passionate about the health and wellness of people living with arthritis, Arthritis Consumer Experts (ACE) is seeking its own champions in the community through our program – Canada’s Best Workplaces for Employees Living with Arthritis Awards.

#Goals4Arthritis BannerThrough a rigorous selection process using wide-ranging criteria, ACE will evaluate Canadian companies that apply best arthritis strategies and practices in the workplace. The application process will deliver insights to further strengthen Canadian companies’ approaches to creating a more productive and arthritis-friendly work environment. And it is an opportunity for employers and employees to assess their companies’ awareness of arthritis and their support systems for employees living with the disease, and be awarded recognition for doing so. To apply for Canada’s Best Workplaces for Employees Living with Arthritis Awards, click here.

Today’s #Goals4Arthritis is to nominate a company who you feel is a great arthritis champion, providing employees living with arthritis a healthy and positive workplace.

#Goals4Arthritis – Goal 18: Sunday Funday

#Goals4Arthritis – Goal 18: Sunday Funday

Happy Sunday!

Today’s #Goals4Arthritis is to have some Sunday fun with your kids, friends, or loved ones. Whether you are watching the FIFA World Cup or enjoying the sunshine outdoor, we hope you get some much needed rest, relaxation, and pleasure from your day’s activities.

#Goals4Arthritis Banner

For our friends in the community who are over 50 years old and have osteoarthritis, here are some activities you can do with your children:

  • Share a hobby or class. This can be dancing, golfing, gardening or swimming. Participating in low-impact exercises can keep joints flexible and muscles strong.
  • Go running or jogging with your loved ones. Determine a routine that can cater to your own flexibility, strength, and ability.
  • Play some table top games like billiards, air hockey, foosball, or table tennis. These activities help keep you active and prevent stiffness in your joints.
  • Cook with your loved ones. Cooking up a hearty meal at home can reduce your intake of added calories and fat as you have total control of which ingredients to use. Every pound of extra weight you lose takes four pounds of pressure off your knees.
  • Do some arts and crafts to keep the small muscles of your joints in motion. It will also alter your focus and concentration to something other than your arthritis pain.